Review Article Open Access
The purpose of this study is to give a broad overview of the main challenges faces to Multinational companies (MNCs) of pharmaceuticals in Pakistan. The aim of study is also investigate ethical challenges of pharmaceutical companies in Pakistan. In Pakistan market pharmaceutical companies influence the physicians’ or professionals and some time force them to prescribe their products by all means. In Pakistan, there is no strong mechanism to monitor the drug promotional movement by pharmaceutical industry although the fact is that there is sufficient evidence that irrational pharmacotherapy is gradually more encountered even in the urban countries due to unethical practices of pharmaceutical promotion. This paper focus on the MNCs Pharmaceutical industry and the changes that have occurred exacting over the last 10 years as a result of the overall economic decline, the increasing cost of healthcare, unethical practice and lack of quality. Some major challenges facing the complex MNCs Pharmaceutical business are focused and discussed in this article. This include the unethical practice of general physicians, decline in the new discovery, approval and marketing of new chemical entities (NCE) or drugs, competition from generics drugs, low quality products, corruption in regulatory authorities in Pakistan, regulatory pressures, slow growth in the Pakistan market (potential market) and therefore the need to explore other markets. We have also discussed in this article some local and MNCs brand quality, and we found that MNCs are meeting qualities parameters. There is strong proof that associations between local industry and physicians influence the prescribing behavior along with clinical decision making.
To read the full article Peer-reviewed Article PDF
| Peer-reviewed Full Article
Author(s): Yasir Mehmood*
MNCs, Unethical, Competition, Regularity, Pharmacotherapy, Pharmacy Practice, Clinical Pharmacy, Patient care